CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
ActivTrades
News & Analysis
Market analysis

Positive Earnings Season Continues to Drive Record Highs

Frank Sohlleder
February 07, 2025

Thursday was once again a celebration for investors and traders in the European stock markets. Thanks to strong earnings reports during the ongoing earnings season, European stock indices continue to reach record highs. In the Euro Stoxx, which closed near its 25-year high, banking stocks were once again the main driver, pushing the index up by over 1.7% on the day. Shares of the Dutch ING Bank surged by more than 6%, while shares of BBVA, Santander, and Unicredit each climbed by more than 3.5%.


DAX Shines with New Record Highs – BASF Leads the Way

The German DAX index hit another all-time high, delivering a daily gain of 1.5% and closing just below the 22,000-point mark at 21,913 points. Investors appear to be setting aside concerns regarding U.S. tariffs and are instead pricing in a positive outlook. The index was primarily driven by the shares of chemical giant BASF, which posted a gain of over 7% by the end of the trading day. Siemens Healthineers also performed strongly, with its impressive earnings results leading to a more than 5% rise in its stock price.


Rate Cut in the UK Pushes FTSE 100 to Record High

The Bank of England’s decision to soften its conservative stance also led to gains in the UK stock market, bringing smiles to investors in the FTSE 100. The index capitalized on the positive momentum, reaching a new record high. The interest rate was cut by 25 basis points as expected, and the outlook for further rate cuts in the near future contributed to the positive trading day. The decision was unanimous, with two board members even advocating for a 50-basis-point cut. AstraZeneca also made headlines with its 19% revenue growth, which led to a 5% rise in its stock price.



The information provided does not constitute investment research. The material has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and as such is to be considered to be a marketing communication.

 

All information has been prepared by ActivTrades (“AT”). The information does not contain a record of AT’s prices, or an offer of or solicitation for a transaction in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information.

 

Any material provided does not have regard to the specific investment objective and financial situation of any person who may receive it. Past performance is not a reliable indicator of future performance. AT provides an execution-only service. Consequently, any person acting on the information provided does so at their own risk.

ActivTrades x Nikola Tsolov
Nikola Tsolov's car